甘露聚糖肽致严重输液反应影响因素分析及预防策略

doi:10.5246/jcps.2022.12.081

中国药学(英文版) ›› 2022, Vol. 31 ›› Issue (12): 953-958.DOI: 10.5246/jcps.2022.12.081

甘露聚糖肽致严重输液反应影响因素分析及预防策略

王志鹏^#, 查华联^#, 温炳钦, 朱健恩, 魏理^*(), 喻鹏久^*()

广州医科大学附属第一医院药学部, 广东广州 510120

收稿日期:2022-10-07 修回日期:2022-10-28 接受日期:2022-11-05 出版日期:2022-12-27 发布日期:2022-12-28
通讯作者: 魏理, 喻鹏久
作者简介:
+ Tel.: +86-13580437446, E-mail: ypj725@163.com
+ Tel.: +86-18928868279, E-mail: runkingone@126.com
基金资助:
Guangzhou Municipal Science and Technology Bureau (Grant No. 202102010186 and 202102010313).

Analysis of influencing factors and preventive strategies for severe infusion reactions induced by mannatide

Zhipeng Wang^#, Hualian Zha^#, Bingqin Wen, Jianen Zhu, Li Wei^*(), Pengjiu Yu^*()

Department of Pharmacy, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China

Received:2022-10-07 Revised:2022-10-28 Accepted:2022-11-05 Online:2022-12-27 Published:2022-12-28
Contact: Li Wei, Pengjiu Yu
About author:
# Zhipeng Wang and Hualian Zha contribute equally to this manuscript.

摘要/Abstract

摘要：

近年来, 随着甘露聚糖肽在临床中的广泛应用, 输液反应的数量不断增加。本研究通过回顾性分析2017–2021年在单一医疗中心报告的38例甘露聚糖肽致输液反应, 通过卡方检验分析严重输液反应的独立高危因素。结果发现, 甘露聚糖肽所致输液反应主要发生在50岁以上(71.05%), 且多发生在给药后10分钟内(86.84%), 有基础疾病史和药物过敏史的患者出现甘露聚糖肽所致严重输液反应风险更高。因此, 对于高龄、既往有药物过敏史、基础病史、首次使用该药的患者, 尤其是给药后10分钟内, 应高度警惕并密切监护。

关键词: 甘露聚糖肽, 输液反应, 过敏史, 基础疾病

Abstract:

In recent years, the number of intravenous infusion reactions has been increasing with the wide application of mannatide in clinical practice. In the present study, 38 cases of mannatide-induced infusion reactions reported in a single medical center from 2017 to 2021 were retrospectively analyzed. Moreover, independent high-risk factors for severe infusion reactions were assessed by the Chi-square test. The results showed that infusion reactions caused by mannatide mainly occurred in patients over 50 years old (71.05%) and primarily occurred within 10 min of drug administration (86.84%), and patients with underlying diseases or drug allergies suffered from severe infusion reactions caused by mannatide. Therefore, the patients with advanced age, previous history of drug allergy, basic medical history, and the first use of this drug, especially within 10 min after administration, should be highly vigilant and closely monitored.

Key words: Mannatide, Infusion reactions, Allergy history, Underlying diseases

Supporting:

王志鹏, 查华联, 温炳钦, 朱健恩, 魏理, 喻鹏久. 甘露聚糖肽致严重输液反应影响因素分析及预防策略[J]. 中国药学(英文版), 2022, 31(12): 953-958.

Zhipeng Wang, Hualian Zha, Bingqin Wen, Jianen Zhu, Li Wei, Pengjiu Yu. Analysis of influencing factors and preventive strategies for severe infusion reactions induced by mannatide[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(12): 953-958.

图/表 3

参考文献 15

[1]	Rombouts, M.D.; Swart, E.L.; VAN DEN Eertwegh, A.J.M.; Crul, M. Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment. Anticancer Res. 2020, 40, 1201–1218.
[2]	Price, M. Acute infusion-related reactions: how to recognize and intervene when these reactions occur in practice. Clin. J. Oncol. Nurs. 2021, 25, 591–594.
[3]	Fouda, G.E.; Bavbek, S. Rituximab hypersensitivity: from clinical presentation to management. Front. Pharmacol. 2020, 11, 572863.
[4]	Zhang, J.L.; Xu, C.; Wan, Y.L.; Gao, M.X. Effects of extremely low frequency magnetic field on production of mannatide by α-hemolytic Streptococcus. Bioelectromagnetics. 2016, 37, 331–337.
[5]	Wang, W.; Li, Y.Q.; Wang, Y.W.; Ren, S.T.; Li, Y.P.; Wang, B. Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine. Int. Immunopharmacol. 2018, 54, 95–102.
[6]	Wang, W.W.; Wang, W.; Xu, W.J.; Liu, Q.; Zhang, Y.X.; Liu, X.H. Polyactin A and CpG enhance inactivated Pseudomonas plecoglossicida vaccine potency in large yellow croaker (Larimichthys crocea). Fish Shellfish. Immunol. 2022, 120, 133–138.
[7]	Wang, M.; Wang, B.; Fang, W.T. CD8⁺ T-cell percentage increases in diffuse large B-cell lymphoma patients receiving mannatide combined with standard regimens. J. Clin. Pharm. Ther. 2021, 46, 832–837.
[8]	Ao, J.F. Analysis of related factors in 9 cases of adverse reactions caused by mannan peptide. Anti-infective Pharmacy. 2018, 15, 830–832.
[9]	Żelechowska, P.; Brzezińska-Błaszczyk, E.; Różalska, S.; Agier, J.; Kozłowska, E. Mannan activates tissue native and IgE-sensitized mast cells to proinflammatory response and chemotaxis in TLR4-dependent manner. J. Leukoc. Biol. 2021, 109, 931–942.
[10]	Muallaoglu, S.; Disel, U.; Mertsoylu, H.; Besen, A.; Karadeniz, C.; Taner Sumbul, A.; Abali, H.; Ozyilkan, O. Acute infusion reactions to chemotherapeutic drugs: a single institute experience. J. Buon. 2013, 18, 261–267.
[11]	Jörg, L.; Yerly, D.; Helbling, A.; Pichler, W. The role of drug, dose, and the tolerance/intolerance of new drugs in multiple drug hypersensitivity syndrome. Allergy. 2020, 75, 1178–1187.
[12]	Zhao, D.H.; Chu, M.M.; Chen, J.; Wang, J.S. Meta-analysis of gemcitabine at 30 Min standard-dose infusion versus prolonged low-dose infusion for advanced non-small cell lung cancer. J. Chin. Pharm. Sci. 2017, 26, 763–770.
[13]	Bu, Y.S.; Xu, Y.G.; Cui, W.; Zhang, L.Y.; Gu, Y.F.; Sun, J.S. Analysis and research on the incidence and related factors of adverse events related to infusion in some medical institutions in Tianjin. Chin. Pharm. J. 2012, 47, 155–158.
[14]	Si, K.Y.; Wang, L.J. Report of 12 cases of adverse reactions caused by intravenous infusion of mannan peptide. Eva. Anal. Med. Chin. Hosp. 2017, 17, 116–118.
[15]	Zhang, J.W.; Yang, M.Z. Analysis on the relative factors of severe allergic reaction induced by mannatide. Chin. J. Hosp. Pharm. 2014, 34, 946–949.

甘露聚糖肽致严重输液反应影响因素分析及预防策略

Analysis of influencing factors and preventive strategies for severe infusion reactions induced by mannatide

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 15

相关文章 0

编辑推荐

Metrics

本文评价